Jean Lopategui, MD, reflects on the use of molecular testing for patients with non–small cell lung cancer.
Girish Putcha, MD, PhD, provides insight on the study results and highlights the advantages of using a multiomic, blood-based assay in colorectal cancer screening.
Andrea Cercek, MD, shares insight on treatment selection, the importance of molecular testing, and unanswered questions with tumor sidedness in patients with newly diagnosed metastatic colorectal cancer.
Despite a reasonable expectation that expression of HER3 and its ligand heregulin would be predictive biomarkers for HER3-targeted therapy, their usefulness in clinical trials has been hit-and-miss. Nevertheless, investigators have persevered, and new types of drugs have largely supplanted the first generation in clinical trials.
James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.
Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.
Although PD-L1 expression is the most established yardstick of response to immune checkpoint immunotherapy, its clinical utility as a biomarker remains an enigma further complicated by the variety of assays and algorithms for measuring it.
The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.
Recent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.
Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.